NAU IB Capital (KOSDAQ:293580)
1,650.00
+88.00 (5.63%)
At close: Jun 12, 2026
NAU IB Capital Revenue
NAU IB Capital had revenue of 4.35B KRW in the quarter ending March 31, 2026, a decrease of -59.83%. This brings the company's revenue in the last twelve months to 14.17B, down -36.63% year-over-year. In the year 2025, NAU IB Capital had annual revenue of 20.64B with 46.41% growth.
Revenue (ttm)
14.17B
Revenue Growth
-36.63%
P/S Ratio
11.03
Revenue / Employee
n/a
Employees
n/a
Market Cap
156.30B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 20.64B | 6.54B | 46.41% |
| Dec 31, 2024 | 14.10B | -5.66B | -28.64% |
| Dec 31, 2023 | 19.76B | 5.83B | 41.86% |
| Dec 31, 2022 | 13.93B | -11.63B | -45.50% |
| Dec 31, 2021 | 25.56B | 15.71B | 159.48% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Devsisters corporation | 264.97B |
| HLB Pharmaceutical | 236.59B |
| KG Financial | 235.07B |
| iFamilySC | 224.55B |
| Daihan Pharmaceutical | 211.44B |
| INSUN Environmental New Technology | 186.30B |
| Seronics | 159.39B |
| Wonik | 151.10B |